Misonix Incorporated Key Opinion Leaders Train New Users At The Congress Of Neurological Surgeons Annual Meeting

FARMINGDALE, N.Y., Oct. 28, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, educated Neurosurgeons and Spine Surgeons at this year’s Annual Meeting of the Congress of Neurological Surgeons (“CNS”) from October 20 to 22, 2014.

“The CNS meeting was an excellent opportunity for us to engage our customers and connect with our distribution network,” commented Michael A. McManus, Jr., President and CEO of Misonix.

At its tradeshow booth, the Misonix team featured two of its ultrasonic therapeutic devices: the BoneScalpel System and the SonaStar^® Aspiration System.

The SonaStar system provides precise and effective soft and hard tissue ablation with maximum control during neurosurgery and other various surgical procedures. The BoneScalpel is an ultrasonic device that offers a clean, controlled bone incision while sparing neural elements and reducing blood loss¹.

At its booth, Misonix hosted several Meet the Expert sessions that were moderated by:

• Dr. Eric J. Woodard, New England Baptist Hospital, Boston, MA;
• Dr. Gregory Trost, University of Wisconsin, Madison, WI;
• Dr. Nicholas Renaldo, Vassar Brothers Medical Center, Poughkeepsie, NY; and
• Dr. Juan Uribe, University of South Florida, Tampa, FL.

Dr. Trost explained, “The CNS meeting was the perfect venue for surgeons to learn about the BoneScalpel and receive a hands-on demonstration showcasing the product’s benefits in spine surgery.”

“The BoneScalpel is an innovative surgical instrument that offers spine surgeons the ability to protect the spinal neural elements when incising and removing bone. The BoneScalpel also improves surgical efficiency while reducing blood loss,” Dr. Trost continued.

Mr. McManus concluded, “The Meet the Expert Sessions were well attended and gave surgeons the opportunity to trial the BoneScalpel under the expert guidance of current users.”

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

1. Bartley, MA, Bastrom, MA, Newton MD, Blood Loss Reduction During Surgical Correction of Adolescent Idiopathic Scoliosis Utilizing an Ultrasonic Bone Scalpel., Spine Deformity, 2 (2014), 285-290.

SOURCE Misonix, Inc.